CareDx says final Medicare LCD maintains coverage for transplant rejection surveillance tests
CDNA•CDNA•CDNA•CDNA•The final LCD was published July 16, 2026, and is effective Aug. 30, 2026.
CareDx said the decision reduces reimbursement uncertainty for key transplant testing products.
CareDx clarified that Medicare finalized a Local Coverage Determination supporting molecular surveillance testing for solid organ transplant rejection.
The policy maintains coverage across kidney, heart, and lung offerings, while setting surveillance test frequency limits for years 1-3 post-transplant. For-cause testing is unchanged.
